Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

Background A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical...

Descrición completa

Detalles Bibliográficos
Main Authors: Remo H. M. Furtado, Ramkumar V. Venkateswaran, Jose C. Nicolau, Yared Gurmu, Deepak L. Bhatt, Robert F. Storey, P. Gabriel Steg, Giuglia Magnani, Shinya Goto, Mikael Dellborg, Gabriel Kamensky, Daniel Isaza, Philip Aylward, Per Johanson, Marc P. Bonaca
Formato: Artigo
Idioma:English
Publicado: Wiley 2020-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
arrhythmias
caffeine
cardiovascular outcomes
dyspnea
ticagrelor
Acceso en liña:https://www.ahajournals.org/doi/10.1161/JAHA.119.015785

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.015785

Títulos similares